(HALO) Halozyme Therapeutics - Overview
Stock: Enzyme, Injection, Antibody, Oncology, Autoimmune
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 40.1% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 30.58 |
| Character TTM | |
|---|---|
| Beta | 0.543 |
| Beta Downside | 0.611 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.86% |
| CAGR/Max DD | 0.47 |
Description: HALO Halozyme Therapeutics January 08, 2026
Halozyme Therapeutics (NASDAQ:HALO) is a biopharma company that commercializes its patented recombinant human hyaluronidase enzyme (rHuPH20) to enable sub-cutaneous delivery of a wide range of injectable therapeutics, from monoclonal antibodies to small-molecule drugs.
Its flagship products include Hylenex ® (rHuPH20 for enhanced SC absorption), XYOSTED™ (SC testosterone replacement), and a pipeline of enzyme-device combos such as ATRS-1902. Halozyme also supplies the enzyme platform for partnered biologics-including Herceptin Hylecta, Phesgo, Mabthera SC, HYQVIA, Ocrevus, DARZALEX, and several HIV, oncology, and autoimmune indications-through licensing deals with Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, BMS, and others.
Key recent metrics: Q4 2023 revenue of $84 million (+27 % YoY), cash and equivalents of $310 million, and a 2024 guidance of $350-$380 million total revenue, driven largely by expanding SC formulations in oncology and immunology. The global sub-cutaneous drug delivery market is projected to grow at a CAGR of ~9 % through 2030, providing a secular tailwind for Halozyme’s enzyme platform.
Strategically, the company’s value hinges on the breadth of its partnership network and the ability to monetize rHuPH20 through royalty streams and upfront payments; any material loss of a major partner (e.g., Roche) would materially downgrade its cash-flow outlook.
For a deeper, data-driven look at Halozyme’s valuation assumptions and scenario analysis, you may find the research tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 595.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 8.58 > 1.0 |
| NWC/Revenue: 39.55% < 20% (prev 107.5%; Δ -67.93% < -1%) |
| CFO/TA 0.28 > 3% & CFO 611.0m > Net Income 595.5m |
| Net Debt (1.09b) to EBITDA (886.4m): 1.23 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.3m) vs 12m ago -6.00% < -2% |
| Gross Margin: 84.55% > 18% (prev 0.78%; Δ 8376 % > 0.5%) |
| Asset Turnover: 57.28% > 50% (prev 44.73%; Δ 12.56% > 0%) |
| Interest Coverage Ratio: 43.01 > 6 (EBITDA TTM 886.4m / Interest Expense TTM 17.8m) |
Altman Z'' 4.85
| A: 0.22 (Total Current Assets 1.33b - Total Current Liabilities 837.2m) / Total Assets 2.22b |
| B: 0.23 (Retained Earnings 502.1m / Total Assets 2.22b) |
| C: 0.35 (EBIT TTM 763.7m / Avg Total Assets 2.17b) |
| D: 0.28 (Book Value of Equity 480.0m / Total Liabilities 1.72b) |
| Altman-Z'' Score: 4.85 = AA |
Beneish M -3.03
| DSRI: 0.92 (Receivables 346.0m/285.7m, Revenue 1.24b/947.4m) |
| GMI: 0.93 (GM 84.55% / 78.34%) |
| AQI: 0.85 (AQ_t 0.37 / AQ_t-1 0.43) |
| SGI: 1.31 (Revenue 1.24b / 947.4m) |
| TATA: -0.01 (NI 595.5m - CFO 611.0m) / TA 2.22b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of HALO shares?
Over the past week, the price has changed by +13.28%, over one month by +11.08%, over three months by +18.77% and over the past year by +40.20%.
Is HALO a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HALO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78 | -4% |
| Analysts Target Price | 78 | -4% |
| ValueRay Target Price | 92.7 | 14.2% |
HALO Fundamental Data Overview February 05, 2026
P/E Forward = 8.5985
P/S = 7.2364
P/B = 16.7347
P/EG = -2.5
Revenue TTM = 1.24b USD
EBIT TTM = 763.7m USD
EBITDA TTM = 886.4m USD
Long Term Debt = 800.1m USD (from longTermDebt, last quarter)
Short Term Debt = 710.7m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.09b USD (from netDebt column, last quarter)
Enterprise Value = 9.80b USD (8.99b + Debt 1.51b - CCE 702.0m)
Interest Coverage Ratio = 43.01 (Ebit TTM 763.7m / Interest Expense TTM 17.8m)
EV/FCF = 16.27x (Enterprise Value 9.80b / FCF TTM 602.4m)
FCF Yield = 6.15% (FCF TTM 602.4m / Enterprise Value 9.80b)
FCF Margin = 48.47% (FCF TTM 602.4m / Revenue TTM 1.24b)
Net Margin = 47.91% (Net Income TTM 595.5m / Revenue TTM 1.24b)
Gross Margin = 84.55% ((Revenue TTM 1.24b - Cost of Revenue TTM 192.1m) / Revenue TTM)
Gross Margin QoQ = 84.41% (prev 85.77%)
Tobins Q-Ratio = 4.41 (Enterprise Value 9.80b / Total Assets 2.22b)
Interest Expense / Debt = 0.28% (Interest Expense 4.30m / Debt 1.51b)
Taxrate = 19.97% (43.7m / 219.0m)
NOPAT = 611.2m (EBIT 763.7m * (1 - 19.97%))
Current Ratio = 1.59 (Total Current Assets 1.33b / Total Current Liabilities 837.2m)
Debt / Equity = 3.00 (Debt 1.51b / totalStockholderEquity, last quarter 503.9m)
Debt / EBITDA = 1.23 (Net Debt 1.09b / EBITDA 886.4m)
Debt / FCF = 1.81 (Net Debt 1.09b / FCF TTM 602.4m)
Total Stockholder Equity = 420.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.45% (Net Income 595.5m / Total Assets 2.22b)
RoE = 141.6% (Net Income TTM 595.5m / Total Stockholder Equity 420.7m)
RoCE = 62.56% (EBIT 763.7m / Capital Employed (Equity 420.7m + L.T.Debt 800.1m))
RoIC = 31.68% (NOPAT 611.2m / Invested Capital 1.93b)
WACC = 6.81% (E(8.99b)/V(10.50b) * Re(7.92%) + D(1.51b)/V(10.50b) * Rd(0.28%) * (1-Tc(0.20)))
Discount Rate = 7.92% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.38%
[DCF Debug] Terminal Value 85.23% ; FCFF base≈518.5m ; Y1≈639.6m ; Y5≈1.09b
Fair Price DCF = 196.3 (EV 24.17b - Net Debt 1.09b = Equity 23.08b / Shares 117.6m; r=6.81% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 42.84 | EPS CAGR: -40.72% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.65 | Revenue CAGR: 39.38% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg30d=-0.048 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=8.18 | Chg30d=+0.050 | Revisions Net=+0 | Growth EPS=+24.8% | Growth Revenue=+26.6%